Scientists are a step closer to developing a pill to cure dementia.
A team in Belgium were able to repair diseased brain cells taken from patients with a common form of the condition, for which there is no cure.
They identified a gene variant that prevents neurons from forming properly, and managed to correct it through genetic engineering.
The researchers found they could also correct alter the gene a compound that inhibited a chemical responsible for the gene mutation.
They have hailed the discovery a breakthrough, believing it could pave the way for a new ‘dementia pill’.
The study used stem cells from three patients with a type of dementia called ‘frontotemporal dementia’, which accounts for about half of cases diagnosed in patients before the age of 60.
There is currently no cure for this type of the condition, which runs in families.
Frontotemporal disorders are the result of damage to neurons in parts of the brain called the frontal and temporal lobes, gradually leading to behavioural symptoms or language and emotional problems.
Mutations in a gene called GRN (progranulin) are believed to be behind frontotemporal dementia, but versions of the condition in mice do not mimic all the features of the human type.
So the Belgian researchers recreated dementia in a laboratory dish using human iPSCs (induced pluripotent stem cells) to help identify a potential new treatment strategy.
Molecular biologist Professor Catherine Verfaillie, of the Catholic University of Leuven, said: ‘Use of induced pluripotent stem cell technology makes it possible to model dementias that affect people later in life.’
The technique involves taking skin cells from patients and reprogramming them into embryonic like stem cells capable of turning into other specific cell types relevant for studying a particular disease.
The Latest on: Dementia pill
via Google News
The Latest on: Dementia pill
- Reassessment of Alzheimer’s Drug Raises Hope—and Concernson December 6, 2019 at 12:19 pm
Some Alzheimer’s experts accept Biogen’s explanation and say they hope the U.S ... Biogen is planning a follow-up study to allow anyone in previous aducanumab trials access to the medication. In ...
- Is it forgetfulness or signs of dementia?on December 6, 2019 at 9:33 am
Memory impairment affects more than 40% of adults over the age of 65 ... Respite care usually takes place in a skilled nursing facility and offers a medically supervised environment, meals, social ...
- Alzheimer's drug could reduce cognitive decline by up to 40%on December 6, 2019 at 2:31 am
Scientists have developed a drug that could slow the progression of Alzheimer’s, research suggests. A team from the pharmaceutical giant Biogen found the IV medication aducanumab may reduce “clinical ...
- Drug Can Curb Dementia’s Delusions, Researchers Findon December 5, 2019 at 10:04 pm
the Alzheimer's Association's chief science officer. The drug is pimavanserin, a daily pill sold as Nuplazid by Acadia Pharmaceuticals Inc. It was approved for Parkinson's-related psychosis in 2016 ...
- Drug helped dementia patients curb their hallucinations and delusionson December 5, 2019 at 7:06 pm
It would also be the first new medicine for Alzheimer’s in nearly two decades. The daily pill targets some of the most troubling symptoms that patients and caregivers face — hallucinations that often ...
- Biogen Has More Hope Than Data for Alzheimer’s Drugon December 5, 2019 at 4:09 pm
(Bloomberg Opinion) -- No drug for Alzheimer’s disease does anything but treat symptoms of the degenerative ... The company presented an expanded case for the medication at a medical meeting on ...
- Biogen Points to Enrollment and Dosing to Explain Alzheimer’s Resultson December 5, 2019 at 2:44 pm
And, in that month, Biogen amended the trial to permit patients with ApoE e4—a form of a gene believed to increase the risk of Alzheimer’s—to begin receiving the high dose of the medication, after ...
- Is this Alzheimer's drug a breakthrough for millions? Company unveils mixed resultson December 5, 2019 at 2:35 pm
A pharmaceutical company that discontinued two late-stage studies of an Alzheimer's drug earlier this year shared new data Thursday explaining how high doses of the experimental medication might slow ...
- Researchers Find Drug Can Curb Delusions in Dementia and Alzheimer’s Patientson December 5, 2019 at 1:42 pm
Trial results were disclosed Wednesday at an Alzheimer’s conference in San Diego, the Associated Press reports. Pimavanserin, a daily pill sold under the brand name Nuplazid by Acadia Pharmaceuticals ...
- Ask the doctors: Memory-boosting pills have no real benefiton December 5, 2019 at 9:58 am
Do these products actually help with memory issues? Dear Reader: More than one-third of the United States population ... Until the day that science develops a real brain pill, we advise our patients ...
via Bing News